Join to View Full Profile
35 Park StreetSmilow Cancer Hospital at Yale-New HavenNew Haven, CT 06511
Dr. Krop is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan
Education & Training
Johns Hopkins University School of MedicinePhD, 1996
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins University School of MedicineResidency, 1996 - 1999- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2023 - Present
CT State Medical License 2022 - 2026
MA State Medical License 2002 - 2023
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.Heather A Parsons, Conor Messer, Katheryn Santos, Jakob Weiss, David Merrell
Cell Genomics. 2025-09-09 - Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.Paolo Tarantino, Do Lee, Julia Foldi, Pamela R Soulos, Cary P Gross
Journal of the National Cancer Institute. 2025-08-14 - Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.Matteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, Nadia Harbeck, Sandra M Swain
Journal of the National Cancer Institute. 2025-08-12
Press Mentions
Researchers Aim to Adapt Metastatic Breast Cancer Therapy as Tumors ChangeJuly 2nd, 2025- Early Breast Cancer Highlights from ASCO 2025June 24th, 2025
- Beverly Levy Walk and Block PartyMay 6th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
